THALES
10.11.2021 09:02:05 CET | Business Wire | Press release
Building on the success of the CipherTrust Data Security Platform , Thales has released CipherTrust Intelligent Protection , a new solution that further simplifies operational complexity and strengthens data security efforts with automated processes that discover, protect and control sensitive data anywhere. Faced with overwhelming data growth, organisations can use CipherTrust Intelligent Protection to safeguard all sensitive information without the added cost and complexity of traditional data protection products and services. Once the sensitive data has been discovered and classified based on vulnerability and other risk profiles, the new solution automatically protects at-risk data with encryption and robust access controls.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211110005012/en/
CipherTrust Intelligent Protection is a solution configuration within the Thales CipherTrust Data Security Platform that works together with CipherTrust Manager, CipherTrust Data Discovery and Classification, and CipherTrust Transparent Encryption –an all-in-one solution that delivers a unified approach. CipherTrust Intelligent Protection addresses the evolving challenges of regulatory compliance by facilitating accelerated time to compliance with automatic data protection controls. It also offers easy-to-use, pre-programmed tools to quickly and effectively secure unstructured sensitive data on-premises and in the cloud.
Reducing complexity in data protection with integrated automation
As organisations contend with expanding datasets, permanent work-from-home or hybrid office schemes, and the increased use of multi-cloud services, lack of visibility places their sensitive data at risk. Thales’s 2021 Data Threat Report
found that the use of cloud-based infrastructure exposes new risks as an organisation’s data footprint expands and raises concerns about operational complexity. Less than a quarter (24%) of respondents said they have complete knowledge of where their data is stored. Configurable policies with built-in templates to rapidly discover and classify unstructured sensitive data can be used to protect data on-premises and in the cloud.
“Cloud computing services and data security requirements will only grow more complex as organisations work to keep pace with new and evolving work environments,” said Todd Moore, VP Encryption Products at Thales. “Increased operational complexity demands simplified security procedures, and CipherTrust Intelligent Protection makes it significantly easier for companies to safeguard data proactively based on known vulnerabilities and data privacy regulations, which reduces overall business risk. Intelligent Protection provides the automation so customers can confidently take data security measures into their own hands with an all-in-one solution.”
Accelerating time-to-compliance
Today’s businesses and organisations must remain in compliance with a broad range of regulations and mandates, including GDPR, CCPA, HIPAA, and PCI DSS. Data privacy laws and regulations are never static – new ones appear regularly and existing ones often get enhanced, making it difficult for you to keep pace. An integrated and automated solution helps eliminate blind spots and human error, making a considerable difference in complying with various regulations.
"This all-in-one solution combines the best of the Ground Labs' data discovery technology with Thales’ CipherTrust Data Security Platform to give organizations the power to automatically discover, classify and keep sensitive data secure, whether it's on-premises or in the cloud," said Stephen Cavey, co-founder and chief evangelist of Ground Labs. “Our partnership with Thales underscores our common mission to protect our customers, regardless of where they store their data - and through this collaboration, we can better meet the data security needs of customers today and in the future."
“Managing risk is becoming increasingly burdensome for IT leaders not only because of the volume and sophistication of cyber-attacks but also due to the operational complexity of managing disparate security products and services,” said Frank Dickson, Program Vice President, Security & Trust, IDC . “Truly integrated platforms that automate the discovery, classification and protection of sensitive data can help organisations reduce both hard costs and risks associated with stitching together multivendor solutions while addressing and mitigating soft costs by simplifying data security operations and compliance.”
Uncover and Close Security Gaps
Finding a way to rapidly identify data compliance gaps and potential security risks is of paramount importance. Using the high performance and accurate discovery engine is an extremely useful way to find data subject to regulations that organizations may not realize even exists. CipherTrust Data Discovery and Classification provides risk-based guidance on what specific data to encrypt. Linking this discovery process to CipherTrust Transparent Encryption provides organizations with a fast track to automatically uncover and close security gaps.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005012/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
